PhD Scholarship in Cancer Sciences - Hodgkin lymphoma

Thursday, January 24, 2019

The contribution of CAMK1D to the pathogenesis of Hodgkin lymphoma

An appropriate Masters Degree or Primary Degree Level (first class hons or 2.1 hons) in a relevant discipline

Stipend of €16,000 tax-free per annum, EU tuition fees covered. Non-EU students may have to pay balance of full fees.
Sunday, March 31, 2019

A CV, University transcripts, 2 academic references and a letter of application indicating why you think your skills and experience meet the requirement for the project. For Further Details, please contact via email Professor Paul Murray paul.murray@ul.ie

New approaches to the treatment of Hodgkin lymphoma (HL) are needed to increase survival for patients with resistant or relapsed disease and to reduce the acute and long-term side effects of current therapies that adversely impact on the health and well-being of survivors.
We have shown that Ca+/calmodulin-dependent kinase 1D (CaMK1D), a member of a sub-family of Ca+/calmodulin-dependent protein kinases, is over-expressed in HL. We have generated a series of highly specific CaMK1D inhibitors that inhibit activation of CaMK1D in a dose-dependent manner and we have demonstrated a dose-dependent cytotoxic effect in HL in CAMK1D-overexpressing HL cell lines.

In this project, we will measure the expression and activation of CaMK1D in relation to disease outcomes in HL patients. We will also explore the impact of CaMK1D inhibition on the phenotype of HL cells, including aberrant cellular signalling, in vitro and evaluate the potential therapeutic effects of CaMK1D inhibitors alone and in combination with standard chemo-therapeutics in xenograft models.

The student will receive a broad range of training and there will be opportunities to spend part of the studentship working in the University of Birmingham Cancer Research Centre.

Return to index